From 2024 to 2027, the value of antiarrhythmic medicine sales in Türkiye remained constant at $0.2 USD PPP per capita. In 2028, this value increased to $0.3 USD PPP per capita, marking a 50% increase from the previous year. However, the Compound Annual Growth Rate (CAGR) from 2024 to 2028 is relatively modest at approximately 3.7%, indicating gradual market growth.
Future trends to watch include advancements in cardiac care technologies, government policies on healthcare expenditure, and demographic shifts that could influence the demand for antiarrhythmic medications.
